- Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
For: DLBCL · Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - RecruitingPHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
For: CLL · Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - RecruitingPHASE3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
This study is looking at a new medicine called duvelisib for people in the UK with a specific type of T-cell lymphoma that has come back or not responded to previous treatments. It compares duvelisib to standard treatments like gemcitabine or bendamustine to see if it helps patients live longer without their cancer getting worse.
For: LymphomaBelgium · Czechia · Denmark - RecruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
For: Follicular Lymphoma (FL)United States · Australia · Austria - Active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
For: Lymphoma, Mantle CellUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This study looks at new treatments for Mantle Cell Lymphoma in adults who can't have a stem cell transplant. It compares two drug combinations to see which works better and is safer.
For: Mantle Cell Lymphoma; Non-Hodgkin LymphomaUnited States · Australia · Austria - RecruitingPHASE1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.
For: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc)United States · France · Sweden - Active not recruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with standard treatment (bendamustine and rituximab) for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see which is safer and works better.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - RecruitingPHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
This study is testing a new cell therapy called zamtocabtagene autoleucel for different types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL), when other treatments haven't worked. It looks at how well it works and if it's safe.
For: Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B Cell Lymphoma · High Grade B-cell Lymphoma (HGBCL)United States · Canada - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
For: Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
This study looks at a new drug, golcadomide, combined with standard treatment for follicular lymphoma that's been recently diagnosed and is advanced. We want to see how well this new combination works and if it's safe for patients.
For: Lymphoma, FollicularUnited States · Australia · Brazil